+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5



Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5



Journal of Clinical Oncology 20(2): 476-484



To investigate whether treatment results in intermediate-stage Hodgkin's lymphoma can be improved by rapid application of non-cross-resistant drugs, the 10-drug regimen cyclophosphamide, vincristine, procarbazine, and prednisone (COPP), doxorubicin, bleomycin, and vinblastine (ABV), and ifosfamide, methotrexate, etoposide, and prednisone (IMEP), repeated every 6 weeks, was compared with conventional alternating COPP/doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) administered every 8 weeks. From January 1988 to January 1993, 996 patients in stage I or II Hodgkin's lymphoma with at least one risk factor (massive mediastinal tumor, massive spleen involvement, extranodal disease, elevated ESR, or more than two lymph node areas involved) and all patients in stage IIIA Hodgkin's lymphoma were randomized to receive two cycles of COPP/ABVD or COPP/ABV/IMEP followed by extended-field radiotherapy. Both regimens produced similar rates for treatment responses (complete remission, 93% v 94%), freedom from treatment failure (80% v 79%), and overall survival (88% for both regimens) at a median follow-up time of 7 years. Most serious toxicities during chemotherapy were similar in both regimens. However, World Health Organization grade 3 and 4 leukocytopenia occurred significantly more frequently in the COPP/ABV/IMEP arm (53% v 44% of patients; P =.010). There were no differences in the number of serious infections and toxic deaths during therapy. The number of second malignancies was also the same in both arms (22 each). Alternating COPP/ABVD and rapid alternating COPP/ABV/IMEP in combination with extended-field radiotherapy are equally effective in intermediate-stage Hodgkin's lymphoma and produce excellent long-term treatment results.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047173005

Download citation: RISBibTeXText

PMID: 11786577

DOI: 10.1200/jco.2002.20.2.476


Related references

Rapidly Alternating Copp/Abv/Imep Is Not Superior to Conventional Alternating Copp/Abvd in Combination With Extended-Field Radiotherapy in Intermediate-Stage Hodgkin's Lymphoma: Final Results of the German Hodgkin's Lymphoma Study Group Trial Hd5. Journal of Clinical Oncology 20(2): 476-484, 2002

Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial. Annals of Oncology 15(2): 276-282, 2004

Long-term results of a randomized trial comparing alternating COPP+ABVD versus rapidly alternating COPP+ABV+IMEP followed by extended field radiation in Hodgkins disease. Onkologie 23(Sonderheft 7): 70, 2000

Rapidly alternating COPP + ABV + IMEP is equally effective as alternating COPP + ABVD for Hodgkins disease Final results of two randomized trials for intermediate and advanced stages. Blood 90(10 Suppl. 1 Part 1): 586A, 1997

Chemotherapy of hodgkin's lymphoma with alternating cycles of copp cyclophosphamide vincristine procarbazine prednisone and abvd doxorubicin bleomycin vinblastine and dacarbazine results of the hd1 and hd3 trials of the german hodgkin study group. Medical Oncology and Tumor Pharmacotherapy 6(2): 155-162, 1989

Comparison of COPP/ABVD and COPP/ABV/IMEP in the treatment of Hodgkins Disease Results of HD5 and HD6 studies of the German Hodgkin Study Group. British Journal of Haematology 93(Suppl. 2): 372, 1996

Alternating COPP + ABVD versus rapidly alternating COPP+ABV+IMEP for Hodgkins disease. Annals of Hematology 67(Suppl. ): A74, 1993

BEACOPP, a new dose-escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin's lymphoma: interim report from a trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 16(12): 3810-3821, 1998

The rapidly alternating scheme COPP-ABV-IMEP is equally effective as COPP-ABVD in advanced stages of Hodgkins disease Results of the HD6 study of the GHSG. Blood. 88(10 Suppl. 1 Part 1-2): 92a, 1996

Treatment of advanced Hodgkins disease with COPP-ABVD and COPP-ABV-IMEP and consolidating radiotherapy A report from the German Hodgkins Lymphoma Study Group. Onkologie 23(Sonderheft 7): 71, 2000

Results of EF- versus IF-RT after 2 cycles of COPP/ABVD for intermediate stage Hodgkins disease The interim analysis of the HD8 trial of the German Hodgkin Study Group. Cancer Journal 6(2): 101-102, March-April, 2000

BEACOPP and COPP/ABVD as salvage treatment after primary extended field radiation therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leukemia and Lymphoma 46(11): 1561-1567, 2005

Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 21(19): 3601-3608, 2003

Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Cancer Treatment Reports 71(12): 1203-1207, 1987

Treatment of advanced-stage Hodgkins disease with COPP and COPP alternating with ABVD. British Journal of Haematology 102(1): 118, 1998